Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Arrowhead Pharmaceuticals (ARWR) over the last 8 years, with Q4 2025 value amounting to $163.1 million.

  • Arrowhead Pharmaceuticals' Non-Current Debt fell 6000.19% to $163.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $163.1 million, marking a year-over-year decrease of 6000.19%. This contributed to the annual value of $214.9 million for FY2025, which is 4534.78% down from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Non-Current Debt of $163.1 million as of Q4 2025, which was down 6000.19% from $214.9 million recorded in Q3 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Non-Current Debt peaked at $407.8 million during Q4 2024, and registered a low of $163.1 million during Q4 2025.